Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 2, 2026, 11:12 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 106 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Recombinant Influenza Vaccine Clear all
Completed Phase 2 Interventional Accepts healthy volunteers Results available

A Study to Learn About a Combined COVID-19 and Influenza Shot in Healthy Adults

NCT06237049
View directory record Official record
Conditions
Influenza, Human, SARS-CoV-2 Infection, COVID-19
Interventions
BNT162b2 (Omi XBB.1.5)/RIV, BNT162b2 (Omi XBB.1.5), RIV, Normal saline placebo
Biological · Other
Lead sponsor
Pfizer
Industry
Eligibility
50 Years and older
Enrollment
644 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024
U.S. locations
30
States / cities
Lake Forest, California • Tustin, California • Walnut Creek, California + 22 more
Source: ClinicalTrials.gov public record
Updated Sep 30, 2025 · Synced Oct 2, 2026, 11:12 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

A Study to Evaluate Safety and Immune Response of Novartis Meningococcal ACWY Vaccine In Infants

NCT00474526
View directory record Official record
Conditions
Meningitis, Meningococcal
Interventions
Meningococcal ACWY Conjugate Vaccine, DTaP-IPV-HBV, Hib, Rotavirus, Pneumococcal 7-valent Conjugate Vaccine, HAV, MMR-V, DTaP
Biological
Lead sponsor
Novartis Vaccines
Industry
Eligibility
2 Months to 2 Months
Enrollment
4,545 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2009
U.S. locations
53
States / cities
Bessemer, Alabama • Birmingham, Alabama • Downey, California + 43 more
Source: ClinicalTrials.gov public record
Updated Mar 24, 2014 · Synced Oct 2, 2026, 11:12 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Trial to Evaluate Safety and Immunogenicity of Trivalent Seasonal Influenza Virus-Like Particle (VLP) Vaccine (Recombinant)

NCT00903552
View directory record Official record
Conditions
Seasonal Influenza
Interventions
Influenza VLP Vaccine, Placebo
Biological
Lead sponsor
Novavax
Industry
Eligibility
18 Years to 49 Years
Enrollment
221 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009
U.S. locations
2
States / cities
Pembroke Pines, Florida • Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 18, 2013 · Synced Oct 2, 2026, 11:12 AM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers

Safety and Immunogenicity of Quadrivalent Influenza mRNA Vaccine MRT5407 in Adult Participants18 Years of Age and Older

NCT05553301
View directory record Official record
Conditions
Influenza Immunization
Interventions
Quadrivalent Influenza mRNA Vaccine MRT5407, Quadrivalent Recombinant Influenza Vaccine, Quadrivalent Influenza Standard Dose Vaccine, Quadrivalent Influenza High-Dose Vaccine
Biological
Lead sponsor
Sanofi Pasteur, a Sanofi Company
Industry
Eligibility
18 Years and older
Enrollment
560 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2024
U.S. locations
23
States / cities
Rolling Hills Estates, California • San Diego, California • DeLand, Florida + 16 more
Source: ClinicalTrials.gov public record
Updated Jan 24, 2025 · Synced Oct 2, 2026, 11:12 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers

The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older

NCT06015282
View directory record Official record
Conditions
Influenza, Human
Interventions
Investigational aQIVc, licensed QIVr, licensed aQIV
Biological
Lead sponsor
Seqirus
Industry
Eligibility
50 Years and older
Enrollment
7,741 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2025
U.S. locations
51
States / cities
Tempe, Arizona • Little Rock, Arkansas • Huntington Beach, California + 47 more
Source: ClinicalTrials.gov public record
Updated Apr 27, 2025 · Synced Oct 2, 2026, 11:12 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Evaluating the Safety and Immunogenicity of a H7N9 Vaccine for the Prevention of Influenza H7N9 Disease in Adults 50 to 70 Years Old

NCT02274545
View directory record Official record
Conditions
Influenza A Virus, H7N9 Subtype
Interventions
H7N9 Anhui 2013/AA ca, Inactivated subvirion H7N9 vaccine
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
50 Years to 70 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2014
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated Apr 19, 2017 · Synced Oct 2, 2026, 11:12 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Study With Quadrivalent Recombinant Influenza Vaccine (RIV4) in Participants 9 Through 49 Years of Age.

NCT05513053
View directory record Official record
Conditions
Influenza Immunization
Interventions
Quadrivalent Recombinant influenza vaccine (RIV4) season/2022-2023/NH
Biological
Lead sponsor
Sanofi Pasteur, a Sanofi Company
Industry
Eligibility
9 Years to 49 Years
Enrollment
1,308 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
21
States / cities
Birmingham, Alabama • Jonesboro, Arkansas • San Diego, California + 16 more
Source: ClinicalTrials.gov public record
Updated Sep 9, 2025 · Synced Oct 2, 2026, 11:12 AM EDT
Active, not recruiting No phase listed Observational

Vaccine Responses in Cancer

NCT06605625
View directory record Official record
Conditions
Viral Vaccines
Interventions
Influenza vaccination, SARS-CoV-2 vaccine, Zoster Vaccine Recombinant
Biological
Lead sponsor
Abramson Cancer Center at Penn Medicine
Other
Eligibility
Not listed
Enrollment
250 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2028
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 28, 2025 · Synced Oct 2, 2026, 11:12 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Safety, Reactogenicity and Immunogenicity of Flublok Quadrivalent (Recombinant Influenza Vaccine,Seasonal Formulation)

NCT01959945
View directory record Official record
Conditions
Influenza
Interventions
Flublok® Quadrivalent Influenza Virus Vaccine, Fluarix Quadrivalent® Influenza Virus Vaccine
Biological
Lead sponsor
Protein Sciences Corporation
Industry
Eligibility
6 Years to 17 Years
Enrollment
219 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2014
U.S. locations
1
States / cities
Auburn, Maine
Source: ClinicalTrials.gov public record
Updated Sep 23, 2016 · Synced Oct 2, 2026, 11:12 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

A Study to Assess Tolerability of the Trivalent Recombinant Vaccine in Individuals Aged 18 and Older Using the Vaccinees Perception of Injection Questionnaire

NCT06765187
View directory record Official record
Conditions
Influenza Immunization, Health Volunteers
Interventions
Trivalent Recombinant Influenza Vaccine
Biological
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
1,007 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
1
States / cities
Swiftwater, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 7, 2026 · Synced Oct 2, 2026, 11:12 AM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers

Safety and Immunogenicity of Quadrivalent Influenza mRNA Vaccine MRT5410 in Adult Participants 18 Years of Age and Older

NCT05624606
View directory record Official record
Conditions
Influenza Immunization
Interventions
Quadrivalent Influenza mRNA Vaccine MRT5410, Quadrivalent Recombinant Influenza vaccine RIV4, Quadrivalent Inactivated Influenza Standard Dose QIV-SD, Quadrivalent Inactivated Influenza High Dose QIV-HD
Biological
Lead sponsor
Sanofi Pasteur, a Sanofi Company
Industry
Eligibility
18 Years and older
Enrollment
682 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2024
U.S. locations
23
States / cities
Huntington Park, California • Long Beach, California • North Hollywood, California + 19 more
Source: ClinicalTrials.gov public record
Updated Mar 18, 2025 · Synced Oct 2, 2026, 11:12 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Comparative Safety and Immunogenicity of VAX128A, VAC128B and VAX128C Novel H1N1 Influenza Vaccine in Healthy Adults

NCT01172054
View directory record Official record
Conditions
Influenza
Interventions
VAX128, Placebo
Biological
Lead sponsor
VaxInnate Corporation
Industry
Eligibility
18 Years and older
Enrollment
292 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2011
U.S. locations
2
States / cities
Miami, Florida • Lenexa, Kansas
Source: ClinicalTrials.gov public record
Updated Jul 31, 2012 · Synced Oct 2, 2026, 11:12 AM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers

Evaluating the Safety and Immunogenicity of a Live Attenuated Virus Vaccine to Prevent Influenza H3N2v Disease

NCT02883426
View directory record Official record
Conditions
Influenza
Interventions
H3N2v MN 2010/AA ca live attenuated influenza vaccine (LAIV), H3N2v inactivated subvirion influenza vaccine, Placebo
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
6 Years to 26 Years
Enrollment
1 participant
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2016
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated May 3, 2018 · Synced Oct 2, 2026, 11:12 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Safety Study of Recombinant M2e Influenza-A Vaccine in Healthy Adults

NCT00819013
View directory record Official record
Conditions
Influenza
Interventions
Influenza A Vaccine: ACAM FLU-A, Saline placebo
Biological
Lead sponsor
Sanofi
Industry
Eligibility
18 Years to 40 Years
Enrollment
87 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2009
U.S. locations
3
States / cities
Miami, Florida • Lenexa, Kansas • Tacoma, Washington
Source: ClinicalTrials.gov public record
Updated Jan 19, 2012 · Synced Oct 2, 2026, 11:12 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Comparison of the Safety of Flublok® Versus Licensed IIV in Healthy, Medically Stable Adults ≥ 50 Years of Age

NCT01825200
View directory record Official record
Conditions
Influenza
Interventions
Flublok, Afluria
Biological
Lead sponsor
Protein Sciences Corporation
Industry
Eligibility
50 Years and older
Enrollment
2,640 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013
U.S. locations
14
States / cities
Tucson, Arizona • Coral Gables, Florida • Savannah, Georgia + 11 more
Source: ClinicalTrials.gov public record
Updated Feb 18, 2015 · Synced Oct 2, 2026, 11:12 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety and Immunogenicity of Live Influenza A Vaccine for Avian Influenza H7N7

NCT00922259
View directory record Official record
Conditions
Influenza A
Interventions
Influenza A H7N7 vaccine
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 49 Years
Enrollment
25 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2012
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated Feb 13, 2013 · Synced Oct 2, 2026, 11:12 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers

Comparison of the Immunogenicity, Safety and Reactogenicity of FluBlok, To a Licensed Vaccine In Elderly Adults

NCT00395174
View directory record Official record
Conditions
Influenza
Interventions
Influenza Vaccination
Biological
Lead sponsor
Protein Sciences Corporation
Industry
Eligibility
65 Years and older
Enrollment
870 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2007
U.S. locations
7
States / cities
Baltimore, Maryland • Rochester, Minnesota • Shrewsbury, New Jersey + 3 more
Source: ClinicalTrials.gov public record
Updated Dec 17, 2009 · Synced Oct 2, 2026, 11:12 AM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers

Safety and Immunogenicity of Quadrivalent Influenza mRNA Vaccine MRT5413 in Adult Participants18 Years of Age and Older

NCT05650554
View directory record Official record
Conditions
Influenza Immunization
Interventions
Quadrivalent Influenza mRNA Vaccine MRT5413, Quadrivalent Recombinant Influenza Vaccine, Quadrivalent Influenza Standard Dose Vaccine, Quadrivalent Influenza High-Dose Vaccine
Biological
Lead sponsor
Sanofi Pasteur, a Sanofi Company
Industry
Eligibility
18 Years and older
Enrollment
682 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2024
U.S. locations
28
States / cities
Chula Vista, California • Gardena, California • Long Beach, California + 24 more
Source: ClinicalTrials.gov public record
Updated Mar 19, 2025 · Synced Oct 2, 2026, 11:12 AM EDT
Not listed Phase 1 Interventional Accepts healthy volunteers

Phase 1 Safety Study of Recombinant Influenza Vaccine for Prevention

NCT02015494
View directory record Official record
Conditions
Influenza
Interventions
VAX2012Q
Biological
Lead sponsor
VaxInnate Corporation
Industry
Eligibility
18 Years to 40 Years
Enrollment
316 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
4
States / cities
Lenexa, Kansas • Rochester, New York • Mt. Pleasant, South Carolina + 1 more
Source: ClinicalTrials.gov public record
Updated Mar 6, 2015 · Synced Oct 2, 2026, 11:12 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Simultaneous RZV and aIIV4 Vaccination

NCT05007041
View directory record Official record
Conditions
Pain, Quality of Life, Injection Site Reaction, Adverse Drug Event
Interventions
FLUAD® Quadrivalent, Fluzone® High-Dose Quadrivalent, SHINGRIX®
Biological
Lead sponsor
Duke University
Other
Eligibility
65 Years and older
Enrollment
267 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2023
U.S. locations
2
States / cities
Baltimore, Maryland • Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jul 11, 2024 · Synced Oct 2, 2026, 11:12 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Phase 3 Pivotal Trial of NanoFlu™ in Older Adults

NCT04120194
View directory record Official record
Conditions
Influenza, Human
Interventions
NanoFlu, Fluzone Quadrivalent
Biological
Lead sponsor
Novavax
Industry
Eligibility
65 Years and older
Enrollment
2,654 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
19
States / cities
Hollywood, Florida • Savannah, Georgia • Stockbridge, Georgia + 16 more
Source: ClinicalTrials.gov public record
Updated May 6, 2023 · Synced Oct 2, 2026, 11:12 AM EDT
Not listed Phase 4 Interventional Accepts healthy volunteers

Recombinant Influenza Vaccination in U.S. Nursing Homes

NCT03965195
View directory record Official record
Conditions
Influenza, Influenza -Like Illness, Influenza, Human
Interventions
Recombinant Influenza Vaccine, Standard Dose Quadrivalent Influenza Vaccine
Biological
Lead sponsor
Insight Therapeutics, LLC
Other
Eligibility
18 Years to 120 Years
Enrollment
1,989 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2023
U.S. locations
1
States / cities
Norfolk, Virginia
Source: ClinicalTrials.gov public record
Updated Mar 15, 2023 · Synced Oct 2, 2026, 11:12 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety and Immunogenicity of Priming With Live Attenuated A/H7N9 Influenza Virus Vaccine Followed By Inactivated A/H7N9 Influenza Virus Vaccine With AS03 Adjuvant

NCT02957656
View directory record Official record
Conditions
Influenza A Virus, H7N9 Subtype
Interventions
H7N9 pLAIV, H7N9 pIIV, AS03 adjuvant
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
20 Years to 49 Years
Enrollment
53 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2016
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated Oct 2, 2018 · Synced Oct 2, 2026, 11:12 AM EDT
Completed Phase 2 Interventional

Trivalent Baculovirus-expressed Influenza HA Vaccine in Adults With Non-Hodgkin's B-cell Lymphoma

NCT00307177
View directory record Official record
Conditions
Influenza
Interventions
Trivalent inactivated influenza vaccine, Trivalent Baculovirus-expressed Influenza HA vaccine
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2005
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Dec 5, 2014 · Synced Oct 2, 2026, 11:12 AM EDT